...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: OTC Expert & Grey Market Restrictions

I'm not sure either.  To me, it reads as a blanket statement but how much or what parts apply just to TD I can't decipher.

Share
New Message
Please login to post a reply